National Project Implementation Plan - NVBDCP

insecticides in use in 200 sites, which will be selected to be representative of
the malaria-ecological patterns in the country. Each year around 40-50 such
sites covering all eco-type zones will be covered with states Entomologist unit
and field stations of NIMR and VCRC. This study will help NVBDCP to evolve a
comprehensive insecticide resistance map for the country and will help betterinformed
insecticide policies. DDT continues to be used for kala-azar
elimination. To date widespread resistance has not been reported but
continued vigilance to determine development of resistance is necessary.
Protocols will be developed by RMRI and in collaboration with the Regional
Director. Insecticide resistance for KA vector will be undertaken in at least 3
sites every year and these sites would be selected in consultation with the
affected states.
(e) Pharmaco-vigilance focusing on the first-line ACT and Miltefosine.
As ACT and Miltefosine are newly adopted in country on a large scale, it is
important to monitor safety in the program conditions. In due course, new
partner drugs may be considered for ACT and new promising drugs on Kalaazar
may be added in the list of first line drugs for kala-azar treatment. A
protocol for prospective monitoring, coordinated with drug susceptibility
testing, in 5 sites has therefore been prepared by NIMR and similarly
pharmaco vigilance would be undertaken in 3 districts included under the kalaazar
elimination program by RMRI.
(f) Operational research and impact evaluation
A list of priorities for operational research (malaria & kala-azar) under this
project has been established. The operational research projects will be carried
out by research institutes based in country, where appropriate, in collaboration
with overseas partners. NVBDCP /Regional offices will be co–investigator/
facilitator for all operational research projects. The list includes:
Validation of rapid diagnostic test for Pv and Pf;
Operational experience with ‘rk 39’;[ presently used in the programme]
Trials of alternative ACT; and fixed dose combination
Monitoring of drug resistance – ACT, Miltefosine;
Monitoring of vector susceptibility test;
Evaluation of different delivery models in public private partnerships
including private providers for curative services in malaria control and kalaazar
elimination;
Cost effective active case detection for malaria and kala-azar;
Treatment of PKDL;
Research on shorter duration treatment of kala-azar with combination
drugs;
Increasing the access to diagnostic and treatment services to the poor and
people living in inaccessible areas;
Environmental studies and impact of climate change in relation to disease
87